A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Abstract Text:

M R Loutfy,M Harris,J M Raboud,T Antoniou,C Kovacs,S Shen,S Dufresne,F Smaill,D Rouleau,A Rachlis,K Gough,R Lalonde,C Tsoukas,B Trottier,S L Walmsley,J S G Montaner,

OBJECTIVES: To determine the severity of injection site reactions (ISRs), patient quality of life (QoL) and preference when enfuvirtide is administered by the Biojector (Bioject, Medical Technologies, Inc., Tualatin, OR, USA) relative to standard needles. METHODS: A total of 201 HIV-positive patients on stable enfuvirtide-based therapy (n=184) or initiating such therapy (n=17) were evaluated prospectively after switching from standard needles to the Biojector system. Patients used needles for a minimum of 2 weeks prior to switching to the Biojector. Questionnaires to assess the incidence and severity of ISRs (31-item score) and QoL [Medical Outcomes Study HIV Health Survey (MOS-HIV)] were administered at baseline and following a minimum of 14 days of Biojector use. RESULTS: The median changes in ISR score and number of ISRs following a median of 1.0 month [interquartile range (IQR) 0.9, 1.3] of Biojector use were -3 (IQR -7, 1) and -1 (IQR -3, 1), respectively. The severity of pain (P<0.0001), induration (P<0.0001), pruritus (P<0.0001), nodules (P<0.0001) and erythema (P<0.0001) all decreased with the Biojector. Administration of enfuvirtide with the Biojector was associated with an improved patient QoL (P<0.0001), and was preferred by 72% of patients. CONCLUSIONS: Compared with needles, the Biojector was associated with a decreased severity of ISRs and improved QoL in patients taking enfuvirtide.

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Publishing Authors By Initials

MR Loutfy,M Harris,JM Raboud,T Antoniou,C Kovacs,S Shen,S Dufresne,F Smaill,D Rouleau,A Rachlis,K Gough,R Lalonde,C Tsoukas,B Trottier,SL Walmsley,JS Montaner,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: HIV medicine

VOLUME: 8

Page Numbers: 427-32

Journal Abbreviation: HIV Med.

ISSN: 1464-2662

DAY: 31

MONTH: Oct

YEAR: 2007

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100897392

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.

AFFILIATION: Department of Medicine, University of Toronto, Maple Leaf Medical Clinic, and Department of Family and Community Medicine, St Michael's Hospital, Toronto, Ontario, Canada. Mona.Loutfy@wchospital.ca

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: HIV Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration Related Publications

• A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
• A review of barriers and facilitators of HIV treatment among injection drug users.
• Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
• Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
• Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator related hemorrhagic transformation.
• Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
• Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells.
• Ethical and scientific issues surrounding solid organ transplantation in HIV-positive patients: Absence of evidence is not evidence of absence.
• Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage.
• Genetics of stroke: a review of recent advances.
• Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
• Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.
• Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption
• Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
• MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.
• Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006.
• Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases.
• NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells.
• Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
• Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.
• Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users.
• Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?
• Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
• The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.
• The use of highly active retroviral therapy to reduce HIV incidence at the population level.
• Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release.
• Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
• [Biological markers in spontaneous intracerebral hemorrhage]
• [Commentary] ANTIRETROVIRAL THERAPY: A KEY PART OF THE PUBLIC HEALTH RESPONSE TO INJECTION DRUG USE.
• [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.]